Not finding it? Sign in to also search OpenAlex live.
-
Inhibitor development upon switching from plasma-derived to recombinant factor VIII in previously untreated patients with severe hemophilia A: the PUP-SWITCH study2024 Research and Practice in Thrombosis and Haemostasis article Medicine Hemophilia Treatment and Research Open access
Syna Miri, Frits Richard Rosendaal, Kaan Kavaklı, Peyman Eshghi, Soha Mohammadi Moghaddam, Sara Scardo, +19 more
1citations -
Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?2020 Arthritis Research & Therapy article Medicine Spondyloarthritis Studies and Treatments Open access
Santiago Rodrigues-Manica, Alexandre Rocha Sepriano, Fernando Manuel Pimentel-Santos, Nélia Gouveia, Anabela Barcelos, Jaime Branco, +11 more
25citations -
FRI0293 EFFECTIVENESS OF SWITCHING BETWEEN TNF INHIBITORS IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: IS THE REASON TO SWITCH RELEVANT?2020 Annals of the Rheumatic Diseases conference-abstract Medicine Spondyloarthritis Studies and Treatments
Santiago Rodrigues-Manica, Alexandre Rocha Sepriano, Nélia Gouveia, Anabela Barcelos, Jaime Branco, Miguel Bernardes, +8 more
0citations -
Adalimumab serum concentration to choose a subsequent biological DMARD in patients with rheumatoid arthritis (ADDORA-switch): results of a blinded randomised test-treatment trial
Maike H M Wientjes, Sadaf Atiqi, Gertjan Wolbink, Michael Twahier Nurmohamed, Maarten Boers, Femke Hooijberg, +7 more
4citations -
Real‐world experience of switching from intravenous to subcutaneous vedolizumab maintenance treatment for inflammatory bowel diseases2022 Alimentary Pharmacology & Therapeutics article Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Amber Sales, Amit Levran, Fiona D M van Schaik, +15 more
43citations -
Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab2022 Current Medical Research and Opinion article Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access
Iris Lin, Richard Melsheimer, Rachel H. Bhak, Patrick Lefèbvre, Maral DerSarkissian, Bruno Émond, +4 more
10citations -
Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns2020 Journal of Thrombosis and Haemostasis article Medicine Venous Thromboembolism Diagnosis and Management Open access
Myrthe M. A. Toorop, Nienke van Rein, Melchior C. Nierman, Helga W. Vermaas, Menno Volkert Huisman, Felix J.M. van der Meer, +2 more
14citations -
ABS0645 TREATMENT PATTERNS AND DETERMINANTS OF DMARD SWITCHING IN EUROPEAN RHEUMATOID ARTHRITIS COHORTS: A MULTI-NATIONAL ANALYSIS2025 Annals of the Rheumatic Diseases conference-abstract Medicine Rheumatoid Arthritis Research and Therapies Open access
D. Di Giuseppe, Nils Steinz, J. Sexton, C.A. Hana, H. Lechner-Radner, Daniela Sieghart, +3 more
0citations -
Author’s Response to Letter to the Editor - Re: Lin I, Melsheimer R, Bhak RH, et al. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin. 2022;38(4):613–6272022 Current Medical Research and Opinion letter Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access
Yinong Young‐Xu, Richard Melsheimer, Bruno Émond, Patrick Lefèbvre, Maral DerSarkissian, Angela Lax, +4 more
0citations -
DOP63 Real World Effectiveness, Safety and Pharmacokinetics of Switching Intravenous Vedolizumab Maintenance treatment to Subcutaneous Vedolizumab Therapy for Inflammatory Bowel Disease2022 Journal of Crohn s and Colitis conference-abstract Biochemistry, Genetics and Molecular Biology Inflammatory Bowel Disease Open access
Adriaan Volkers, Tessa Straatmijer, Marjolijn Duijvestein, Andressa Gomes Sales, F van Schaik, M Jeroen, +13 more
2citations -
P326 Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar2020 Journal of Crohn s and Colitis conference-abstract Immunology and Microbiology Biosimilars and Bioanalytical Methods
Shaden Mahmmod, Johannes P. D. Schultheiss, Adriaan C.I.T.L. Tan, Maurice W. M. D. Lutgens, Lennard P. L. Gilissen, Nofel Mahmmod, +5 more
3citations -
Characteristics of High-Risk Polycythemia Vera Patients with Suboptimal Response to First-Line Therapy Who Switched to Ruxolitinib Vs Those Who Did Not Switch: Findings from PV-Switch, a Multinational, Retrospective Chart Review Study
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +9 more
1citations -
Switch to once-weekly, single-tablet islatravir–lenacapavir from daily standard of care for HIV-1 (ISLEND-2): a multicentre, randomised, open-label, active-controlled, phase 3 non-inferiority trial
Amy E. Colson, Princy N. Kumar, Peter Jerome Ruane, Ploenchan Chetchotisakd, Winai Ratanasuwan, Afaaf Liberty, +90 more
3citations -
Clinical outcomes of high-risk patients with polycythemia vera after suboptimal response to first-line therapy who switched to ruxolitinib versus nonswitchers: results from the PV-Switch study2025 Therapeutic Advances in Hematology article Medicine Myeloproliferative Neoplasms: Diagnosis and Treatment Open access
Steffen Koschmieder, Eyck von der Heyde, Lambert Busque, Françoise Boyer‐Perrard, Timothy Devos, Francesco Passamonti, +5 more
2citations -
Switching and Discontinuation Patterns Among Patients Stable on Originator Infliximab Who Switched to an Infliximab Biosimilar or Remained on Originator Infliximab2021 Biologics article Immunology and Microbiology Biosimilars and Bioanalytical Methods Open access
Timothy P. Fitzgerald, Richard Melsheimer, Marie‐Hélène Lafeuille, Patrick Lefèbvre, Laura Morrison, Iris Lin, +1 more
16citations -
Decompressive craniectomy plus best medical treatment versus best medical treatment alone for spontaneous severe deep supratentorial intracerebral haemorrhage: a randomised controlled clinical trial
Jürgen Beck, Christian Fung, Daniel Strbian, Lukas Bütikofer, Werner Josef Z'Graggen, Matthias F. Lang, +43 more
126citations -
Switching between complement inhibitors in patients with PNH: A real-world analysis of strategy, efficacy, and safety.2025 Blood conference-abstract Immunology and Microbiology Complement system in diseases Open access
Morag Griffin, Bruno Fattizzo, Jong Wook Lee, Richard J. Kelly, Roochi Trikha, Yasutaka Ueda, +10 more
0citations